Bladder cancer is the ninth most common cancer worldwide and the fourth most common tumor type among American men (bladder cancer occurs about four times more frequently in men than in women).
The disease consists of several types of malignancies originating in the epithelium of the urinary bladder. Globally approximately 2.5 million people suffer from it, with 420,000 newly diagnosed each year. In 2010 there were 170,000 cases of death from bladder cancer globally, up from 115,000 cases in 1990.
The economic and human toll of bladder cancer represents a health burden disproportionate to its size. It has the highest lifetime cost of care per patient of all cancers in the US due to its high recurrence rate and the invasive and ongoing monitoring required, including lifelong cystoscopy follow-ups.
New therapies for bladder cancer are needed, and no drugs have been approved by the FDA for the treatment of NMIBC in 20 years.
Inodiftagene vixteplasmid addresses both:
Investor relations: Ashley Robinson, LifeSci Advisors